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Lysosomal storage diseases (LSDs) are a group of heterogeneous and 
multisystemic disorders caused by defects in enzymes responsible for the 
intralysosomal degradation of particular compounds. One of them is Lysosomal 
Acid Lipase Deficiency (LALD) that is caused by the deficiency of the enzyme 
Lysosomal Acid Lipase (LAL), which is responsible for the hydrolysis of 
cholesterol esters and triglycerides in the lysosome. Historically, LALD has been 
reported as one of two major clinical presentations: Wolman disease (WD), the 
early onset form characterized by hepatosplenomegaly, adrenal calcification and 
cytopenia, in which death occurs within the first 6 months of age; and 
Cholesterol Ester Storage Disease (CESD), the late onset form characterized by 
an heterogeneous phenotype and unpredictable progression with hepatomegaly 
as the most common manifestation. With the development of enzyme 
replacement therapy for LALD, the early diagnosis of LALD patients became 
imperative, in order to start the treatment before the appearance and/or 
progression of the most deleterious symptoms. The major aim of this work was 
to establish an accurate and feasible method to measure LAL activity in dried 
blood spots (DBS). This assay will be used for the early diagnosis of LALD 
patients, allowing a quick intervention, and preventing the progression of the 
disease, especially in the case of WD, where the progression is very rapid. The 
measurement of LAL activity was done in DBS samples obtained from healthy 
controls with different ages, LALD patients and patients with other lysosomal 
disorders. A specific substrate marked with the fluorescent 4-methylumbelliferyl 
(4-MU), together with 3,4-disubstituted thiadiazole carbamate, as a selective 
inhibithor of Lysosomal Acid Lipase were used to determine the enzymatic 
activity of LAL through a modified version of the method originally described by 
Hamilton et al (1). The results obtained proved that this assay is suitable for the 
biochemical diagnosis of LALD even in very young patients. Once DBS samples 
are easy to collect and to ship, the implementation of this methodology will also 
contribute to the better knowledge of the LALD prevalence in Portugal. Finally, 
the early diagnosis of LALD is fundamental for directing the patients to a more 
efficient treatment as well as for the prevention of the disease.  
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